Title
Category
Credits
Event date
Cost
2020 and Beyond: How Immunotherapy is Changing the Game in Bladder Cancer Management
  • Oncology
  • AAPA Category I CME
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
$0.00
It is estimated that there are >81,000 new cases of metastatic urothelial bladder cancer (mUBC) in the U.S each year, resulting in more than 17,000 bladder cancer specific deaths. For more than three decades, systemic platinum-based chemotherapy has been the standard first-line treatment for patients with inoperable or advanced metastatic bladder cancer.